Seeking Alpha

Ampio Pharmaceuticals updates Optina dose finding study

  • Ampio Pharmaceuticals (AMPE +3.4%) reports interim results from a dose finding trial of Optina in DME.
  • Ultimately, the IDRC recommended the continuation of the trial as "it was determined that there was a treatment dosage that was demonstrating a potentially beneficial anatomic effect [and] there were no significant safety concerns."
  • Once the trial is complete, the company will immediately initiate an open label extension study using the determined optimum dose. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)